NASDAQ:ABIO - ARCA biopharma, Inc.
$0.39
 $-0.01
-1.50%
1:45PM EDT
2019-02-15
ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  ABIO     avg for
industry  
  avg for
sector  
42 stocks weight:  7. 49   0. 00   0. 00  
42 stocks rank:  3. 97 K 1. 86 K 1. 09 K
# analyst opinions:  1. 00   14. 92   14. 43  

quick ratio:  8. 24   5. 37   1. 81  
current ratio:  8. 58   5. 69   2. 19  

target price low:  1. 00   88. 97   117. 82  
target price avg:  1. 00   115. 19   141. 96  
target price high:  1. 00   143. 40   163. 16  
1-yr high:  1. 65   124. 30   142. 77  
last close:  0. 40   101. 85   127. 84  
50-day avg:  0. 41   98. 27   122. 46  
200-day avg:  0. 55   99. 72   122. 70  
1-yr low:  0. 28   78. 19   100. 16  
volume:  135. 78 K 2. 38 M 4. 64 M
50-day avg volume:  144. 82 K 3. 31 M 4. 94 M
200-day avg volume:  663. 21 K 3. 23 M 4. 28 M

1-day return:  -2. 44 % 0. 22 % 0. 48 %
this week return:  8. 11 % 1. 77 % 2. 01 %
12-wk return:  -25. 93 % 6. 56 % 3. 33 %
52-wk return:  -76. 12 % -2. 23 % 14. 35 %

enterprise value (EV):  -2. 90 M 55. 17 B 104. 51 B
market cap:  5. 66 M 49. 01 B 96. 46 B
EBITDA:  -10. 80 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  0. 27   -91. 79   2. 29  
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -10. 64 M 2. 37 B 3. 58 B

shares outstanding:  13. 92 M 607. 99 M 1. 22 B
shares:  13. 76 M 605. 53 M 1. 15 B
shares short:  367. 05 K 11. 62 M 12. 55 M
shares short prior month:  354. 64 K 11. 95 M 13. 44 M
short ratio:  1. 96   4. 82   3. 10  
short % of float:  2. 67 % 6. 19 % 2. 82 %
total cash/share:  0. 58   12. 02   11. 46  
total cash:  8. 06 M 7. 41 B 7. 37 B
free cash flow:  -7. 88 M 95. 99 M 2. 04 B
operating cash flow:  -11. 10 M 164. 74 M 3. 04 B

book value:  0. 54   14. 43   28. 26  
price/book:  0. 75   -1. 57   -2. 97  
operating margins:  0. 00 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  0. 00 % 49. 33 % 54. 53 %

1-yr max volatility:  82. 14 % --- ---
1-yr mean volatility:  0. 01 % 0. 01 % 0. 06 %

1-yr EPS:  -0. 80   3. 03   4. 09  
forward EPS:  -1. 03   4. 33   6. 99  
P/E:  -0. 50   6. 11   26. 91  
forward P/E:  -0. 35   8. 38   10. 48  
PE/G:  0. 01   0. 37   5. 61  
growth:  -66. 02 % 683. 72 % 104. 79 %
earnings high:  -0. 14   1. 27   1. 66  
earnings avg:  -0. 14   1. 01   1. 53  
earnings low:  -0. 14   0. 76   1. 40  
revenue high:  -0. 00   2. 86 B 11. 19 B
revenue avg:  -0. 00   2. 78 B 10. 84 B
revenue low:  -0. 00   2. 67 B 10. 64 B
return on assets:  -53. 65 % -3. 27 % 3. 81 %
return on equity:  -97. 56 % 107. 48 % 27. 82 %

beta (1yr vs S&P500):  0. 05   1. 21   0. 93  
sharpe (1yr):  0. 02   0. 06   0. 98  

held % insiders:  1. 17 % 6. 46 % 3. 21 %
held % institutions:  14. 36 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : ABIO
.        + 0 =             0 :: INITIAL WEIGHT
.  + 435.827 =       435.827 :: inverse volume-to-price addition
.  + 484.737 =       920.564 :: spline projection addition
.  - 200.887 =       719.677 :: poor performance penalty
.    x 0.536 =       386.088 :: one-year gains+dividend factor
.    x 4.034 =      1557.289 :: 13 weeks' performance factor
.    x 1.492 =      2324.236 :: industry recommendation factor
.    x 0.995 =      2311.766 :: return on assets factor
.     x 0.99 =      2289.213 :: return on equity factor
.    x 2.493 =      5706.687 :: current ratio factor
.    x 1.067 =      6088.206 :: quick ratio factor
.    x 1.229 =      7481.818 :: short ratio factor
.    x 2.007 =      15019.47 :: price-to-book factor
.    x 5.656 =     84946.942 :: EBITDA multiple factor
.    x 2.174 =    184699.927 :: P/E weight
.    x 2.209 =    407994.586 :: PE/G factor
.    x 1.614 =    658348.573 :: beta factor
.    x 0.018 =     11542.388 :: sharpe factor
.    x 2.413 =     27852.132 :: target low factor
.    x 1.408 =     39222.717 :: target mean factor
.    x 1.122 =     44026.499 :: target high factor
.    x 1.066 =     46915.202 :: industry 12-weeks return
.    x 0.917 =     43015.214 :: "drift" penalty 1 days ago
.    x 0.976 =     41995.359 :: "drift" penalty 3 days ago
.    x 0.953 =     40017.337 :: "drift" penalty 4 days ago
.    x 0.987 =     39508.289 :: overall "drift" factor
.    x 0.179 =      7055.053 :: largest single-day jump factor
.     x 0.06 =       420.444 :: low price factor
.      x 1.0 =       420.472 :: factor hist industry gain for week 06
.   cubeRoot =         7.492 :: reduced for readability
.                      7.492 :: FINAL WEIGHT for NASDAQ:ABIO


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org